How big is the respiratory care devices market, and what is driving its growth? The global respiratory care devices market is ...

A VA research team has documented the personal values that women veterans express when beginning treatment for obstructive ...

I am protected by a diagnosis. Thousands of Massachusetts residents now face losing access. The state's Group Insurance ...

IntroductionHello everyone. I am Bonno.Are you familiar with the ancient Greek word "Pharmakon"? It is the etymological root of the modern English word "Pharmacy," and it refers to something that ...

A deep-dive comparison of ResMed and Fisher & Paykel Healthcare shares: dividends, valuation, recent momentum, and which I ...

Nearly one-quarter to one-third of U.S. adults have sleep disordered breathing that goes untreated, but there is help for ...

Therapy with GLP-1 RAs reduces the frequency of apnea and hypopnea events in obesity, serving as an effective adjunct to ...

Ending coverage does not merely stop progress. It reverses it—and costs may return as diabetes, CPAP equipment, additional medications, disability, and hospital care.

An opinion piece argues that ending Medi-Cal coverage for GLP-1 medications could shift costs toward treating obesity-related ...

Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing ...

A 2019 analysis published in The Lancet Respiratory Medicine estimated that approximately 936 million adults aged 30 to 69 worldwide have OSA. Through technology, education, provider partnerships and ...

Weight-loss drugs may help reduce sleep apnea symptoms, but experts say they still can’t match the effectiveness of a CPAP machine.